Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well nemtabrutinib in combination with pembrolizumab works in treating patients with Richter transformation, diffuse large B-cell lymphoma subtype (RT-DLBCL). Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cells (a type of white blood cell) in cancers such as Richter transformation at abnormal levels. This may help keep cancer cells from growing and spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving nemtabrutinib in combination with pembrolizumab may kill more cancer cells in patients with RT-DLBCL.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony biopsją nowotwór (transformacja Richtera, podtyp chłoniaka rozlanego z dużych komórek B)
- •Pacjent nie może być leczony standardową chemioterapią lub ma nawrót po wcześniejszym leczeniu
- •Wyzdrowiał ze skutków ubocznych poprzedniej terapii (do poziomu 1 lub mniej)
- •Widoczna choroba w badaniach obrazowych (PET, tomografia, badania krwi)
- •Potrafi łykać i przyjmować leki doustne
- •Wiek 18 lat i więcej
- •Liczba neutrofili ≥500 (bez stymulacji wzrostu w ostatnich 7 dni)
- •Liczba płytek ≥25 000 (bez transfuzji w ostatnich 3 dniach)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Roswell Park Cancer Institute
Buffalo, United States
Trial contact
Matthew J. Cortese
Matthew J. Cortese
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.